Defeat Duchenne Canada Launches New Clinical Trial Finder Tool

Defeat Duchenne Canada is proud to announce the launch of the first Clinical Trial Finder Tool for Duchenne and Becker muscular dystrophy in Canada.

Visit the Clinical Trial Finder Tool

Duchenne and Becker muscular dystrophy are progressive neuromuscular disorders with no cure. Affecting approximately 1 in every 5,000 boys in Canada, both Becker and Duchenne are caused by mutations within the dystrophin gene, one of the largest genes in the body responsible for strengthening muscles and protecting them from injury.

When the organization first began its quest for a cure twenty-six years ago, there was very little research and no clinical trials. Since then, numerous organizations, like Defeat Duchenne Canada, have transformed the landscape by investing in the most promising science focused on prevention, improved treatments, and a better quality of life for individuals living with Duchenne and Becker.

“We have developed an innovative Clinical Trial Finder Tool for those living with Duchenne and Becker muscular dystrophy. The tool helps gather comprehensive information on existing and pending clinical trials in Canada and beyond, allowing our community to easily personalize and navigate the latest information to help make informed choices about their participation,” shares Nicola Worsfold, Vice-President of Research, Advocacy and Education at Defeat Duchenne Canada.

“Being involved in a clinical trial is not a decision that can be made lightly,” she continues. “While it offers the possibility of hope, it also involves many sacrifices from the whole family. We want to empower our community with accurate, up-to-date information to facilitate informed decision making with their health care team.”

Watch the Defeat Duchenne Canada webinar launch of their Clinical Trial Finder Tool

 

Defeat Duchenne Canada has built a foundation of strong partnerships with leading scientists and industry partners to improve care for individuals living with Duchenne and Becker. When they heard the need from their community for more resources regarding clinical trials, the organization turned to Lumiio, a global digital health company specializing in real-world data collection services that drive health outcomes.
“We were thrilled to be able to work with Defeat Duchenne Canada in the development of a tool that helps close knowledge gaps around clinical trial opportunities,” said Josh Lounsberry, Chief Strategy Officer at Lumiio, “The needs of the Duchenne community align perfectly with Lumiio’s mission of accelerating health outcomes through data.”

Learn more about the Clinical Trial Finder Tool defeatduchenne.ca/clinicaltrials

 

Read the full press release from Defeat Duchenne Canada

Defeat Duchenne Canada's Clinical Trial Finder Tool

Read next...

NMD4C launches early career awards for 2022.

NMD4C Early Career Award Nominations Now Open

This initiative will allow NMD4C early-career members to be nominated for one of four awards, celebrating excellence and contribution to the neuromuscular field in both clinical and basic science streams.

MDC-grant-plan-2022

Clinical and Postdoctoral Research Fellowship Funding Competition from NMD4C, MDC, CSCN Now Open!

The NMD4C, in partnership with Muscular Dystrophy Canada (MDC) is now accepting applications for Post-doctoral Research Fellowships and Clinical Fellowships! These competitions are now open, and will close on November 14, 2022.

National Neuromuscular Lecture Series

National Neuromuscular Lecture Series Provides Training Opportunity for Neuromuscular Clinical Fellows

The NMD4C curriculum working group is pleased to share that the inaugural “National Neuromuscular Lecture Series” kicked off this August 12, 2022. This year-long training curriculum for current Canadian neuromuscular fellows has been developed in consultation with the directors of fellowship programs across Canada. The group decided on 41 topics which constitute a comprehensive neuromuscular knowledge base and identified subject-matter experts from across the country to deliver the weekly lectures.

imPORTND - soft launch image

imPORTND Patient-Oriented Research Training for Neuromuscular Disease Seeks Research Teams for Testing

The NMD4C is excited to introduce our online training platform “imPORTND”, created to help scientists engage with patient partners in research. These modules are designed for all neuromuscular research team members including researchers, staff, and patient partners. imPORTND has been co-developed with a team of expert patient partners, clinicians, and researchers, and offer two modules to help scientists engage with patient partners in research. It is the first patient-oriented research training that focuses specifically on neuromuscular disease.

Myotonic dystrophy foundation logo

2023 Myotonic Dystrophy Foundation Early Career Research Grant

The MDF will issue up to two two-year awards of up to $380,000 at $190,000 per award for early career scholars in the DM field for projects that focus on basic, translational and/or clinical research or care projects in myotonic dystrophy.

welcome to the team - Kevin LaFleur

NMD4C Hire Research Software Developer

The NMD4C are pleased to announce the hiring of research software developer Kevin LaFleur as the most recent addition to the network’s biobanking team! Kevin will develop the technical infrastructure for a centralized Canadian neuromuscular biobanking catalogue.